替米沙坦市场报告（按适应症（高血压、降低心血管风险）、配销通路（医院药房、药房和零售药房、网上商店）和地区划分，2025 年至 2033 年

2024 年全球替米沙坦市场规模达 38.3 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 48.2 亿美元，2025-2033 年期间的成长率 (CAGR) 为 2.59%。

替米沙坦是一种非胜肽类血管张力素受体阻断剂 (ARB)，作为处方药用于治疗高血压和心血管疾病。它通常以片剂和口服油混悬剂的形式存在，并与其他药物联合使用以增强疗效。它具有抗高血压特性，并抑制体内醛固酮的生成，从而减少钠和水的吸收，最终降低血压。替米沙坦还能舒张血管，促进肾功能。然而，它可能引起各种副作用，例如头晕、头重脚轻、咳嗽和鼻窦疼痛。

替米沙坦市场趋势：

全球製药业的显着成长是市场前景乐观的关键因素之一。此外，高血压、糖尿病和各种肾臟相关疾病的日益普及也推动了市场的成长。替米沙坦已被证明能够有效改变胰岛素增敏基因，并调节血糖和脂质代谢，有助于控制慢性糖尿病肾病变以及久坐不动的生活方式引起的其他疾病。製药商也正在推出替米沙坦仿製药，以提供经济有效的高血压和心血管疾病治疗方案。此外，製药商正在大力投资用于治疗糖尿病肾病变的先进替米沙坦药物的研发，这也促进了市场的成长。老年人口的成长以及医疗基础设施的显着改善等其他因素预计将进一步推动市场的发展。

本报告回答的关键问题：

• 到目前为止，全球替米沙坦市场表现如何，未来几年将如何表现？
• COVID-19 对全球替米沙坦市场有何影响？
• 主要的区域市场有哪些？
• 根据该迹象，市场将如何分化？
• 根据配销通路，市场是如何分類的？
• 该产业的价值链分为哪些阶段？
• 该行业的主要驱动因素和挑战是什么？
• 全球替米沙坦市场的结构是怎么样的？主要参与者是谁？
• 产业竞争程度如何？

目录

第一章：前言

第二章：范围与方法

• 研究目标
• 利害关係人
• 资料来源
  • 主要来源
  • 二手资料
• 市场评估
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第三章：执行摘要

第四章：简介

第五章：全球替米沙坦市场

• 市场概况
• 市场表现
• COVID-19的影响
• 市场预测

第六章：市场区隔：依指标

• 高血压
• 降低心血管风险

第七章：市场区隔：按配销通路

• 医院药房
• 药局和零售药房
• 网上商店

第八章：市场区隔：依地区

• 北美洲
  • 美国
  • 加拿大
• 亚太
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲
  • 印尼
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 其他的
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他的
• 中东和非洲

第九章：SWOT分析

第 10 章：价值链分析

第 11 章：波特五力分析

第 12 章：价格分析

第 13 章：竞争格局

• 市场结构
• 关键参与者
• 关键参与者简介
  • Abbott Laboratories
  • Aurobindo Pharma USA
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Hikma Pharmaceuticals plc
  • Jubilant Cadista Pharmaceutical
  • Sanofi SA
  • Solco Healthcare (Prinston Pharmaceutical Inc.)
  • Torrent Pharmaceuticals Ltd

The global telmisartan market size reached USD 3.83 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.82 Billion by 2033, exhibiting a growth rate (CAGR) of 2.59% during 2025-2033.

Telmisartan is a non-peptide angiotensin receptor blocker (ARB), which is used as a prescription drug for the treatment of hypertension and cardiovascular disorders. It is commonly available in tablets and oral oil suspension variants and is administered with other medications to enhance its efficacy. It exhibits antihypertensive properties and inhibits aldosterone production in the body, thereby leading to a decrease in sodium and water absorption and subsequent reduction in the blood pressure. Telmisartan also relaxes the blood vessels and promotes kidney function. However, it may cause various side effects, such as dizziness, lightheadedness, cough and sinus pain.

Telmisartan Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing prevalence of high blood pressure, diabetes and various kidney-related disorders is providing a thrust to the market growth. Telmisartan has been proven effective in modifying genes for insulin sensitization and regulating glucose and lipid metabolism, which aids in managing chronic diabetic kidney disease and other disorders caused by sedentary lifestyles. Pharmaceutical manufacturers are also launching generic versions of telmisartan medications to provide cost-effective treatment to hypertension and cardiovascular ailments. Additionally, drug manufacturers are investing significantly in the research and development (R&D) of advanced telmisartan medications for the treatment of diabetic nephropathy, which is also contributing to the growth of the market. Other factors, including the rising geriatric population, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Indication:

• Hypertension
• Cardiovascular Risk Reduction

Breakup by Distribution Channel:

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Stores

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH, Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd.

Key Questions Answered in This Report:

• How has the global telmisartan market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global telmisartan market?
• What are the key regional markets?
• What is the breakup of the market based on the indication?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global telmisartan market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Telmisartan Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Indication

• 6.1 Hypertension
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Cardiovascular Risk Reduction
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacies
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Drug Stores and Retail Pharmacies
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online Stores
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Aurobindo Pharma USA
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
  • 13.3.3 Boehringer Ingelheim International GmbH
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
  • 13.3.4 Cipla Limited
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Hikma Pharmaceuticals plc
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 Jubilant Cadista Pharmaceutical
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
  • 13.3.7 Sanofi S.A.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Solco Healthcare (Prinston Pharmaceutical Inc.)
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
  • 13.3.9 Torrent Pharmaceuticals Ltd
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis

List of Figures

• Figure 1: Global: Telmisartan Market: Major Drivers and Challenges
• Figure 2: Global: Telmisartan Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Telmisartan Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 4: Global: Telmisartan Market: Breakup by Indication (in %), 2024
• Figure 5: Global: Telmisartan Market: Breakup by Distribution Channel (in %), 2024
• Figure 6: Global: Telmisartan Market: Breakup by Region (in %), 2024
• Figure 7: Global: Telmisartan (Hypertension) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 8: Global: Telmisartan (Hypertension) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 9: Global: Telmisartan (Cardiovascular Risk Reduction) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 10: Global: Telmisartan (Cardiovascular Risk Reduction) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 11: Global: Telmisartan (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 12: Global: Telmisartan (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 13: Global: Telmisartan (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 14: Global: Telmisartan (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 15: Global: Telmisartan (Online Stores) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 16: Global: Telmisartan (Online Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 17: North America: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 18: North America: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 19: United States: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 20: United States: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 21: Canada: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 22: Canada: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 23: Asia-Pacific: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 24: Asia-Pacific: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 25: China: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 26: China: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 27: Japan: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 28: Japan: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 29: India: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 30: India: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 31: South Korea: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 32: South Korea: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 33: Australia: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 34: Australia: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 35: Indonesia: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 36: Indonesia: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 37: Others: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 38: Others: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 39: Europe: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 40: Europe: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 41: Germany: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 42: Germany: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 43: France: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 44: France: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 45: United Kingdom: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 46: United Kingdom: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 47: Italy: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 48: Italy: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 49: Spain: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 50: Spain: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 51: Russia: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 52: Russia: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 53: Others: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 54: Others: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 55: Latin America: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 56: Latin America: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 57: Brazil: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 58: Brazil: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 59: Mexico: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 60: Mexico: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 61: Others: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 62: Others: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 63: Middle East and Africa: Telmisartan Market: Sales Value (in Million USD), 2019 & 2024
• Figure 64: Middle East and Africa: Telmisartan Market: Breakup by Country (in %), 2024
• Figure 65: Middle East and Africa: Telmisartan Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Global: Telmisartan Industry: SWOT Analysis
• Figure 67: Global: Telmisartan Industry: Value Chain Analysis
• Figure 68: Global: Telmisartan Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Telmisartan Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Telmisartan Market Forecast: Breakup by Indication (in Million USD), 2025-2033
• Table 3: Global: Telmisartan Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
• Table 4: Global: Telmisartan Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 5: Global: Telmisartan Market: Competitive Structure
• Table 6: Global: Telmisartan Market: Key Players